This outperformance of an established clinical therapy suggests significant potential for diabetic wound applications
Next steps in clinical translation First-in-human safety trials (phase I) are essential: to assess dose tolerability, pharmacokinetics, biodistribution, peptide half-life, clearance, immunogenicity
In age-related diseases and more particularly in IPF, mice treated with FOXO4-DRI display less senescent cells leading to a reduction of the progression of fibrosis 28
GLOW Blend , sometimes referred to as GLOW Mix , combines BPC-157, TB-500, and GHK-Cu into one wellness-focused peptide stack designed to support recovery, mobility, skin wellness, exercise recovery, and overall wellness support
Frequent Infections Vitamin D supports immune regulation